




Supplementary Figure 4. The impact of telomere length in *IGHV*-mutated and *IGHV*-unmutated groups in FCR-treated patients. Dividing the *IGHV*-mutated and *IGHV*-unmutated prognostic groups according to telomere length revealed (A) a significant difference in PFS in the *IGHV*-mutated group with short telomere patients having shorter PFS. (B) Short telomere length in the *IGHV*-unmutated group showed a trend towards reduced PFS but this was not significant. In terms of OS, (C) the *IGHV*-mutated group showed showed a trend towards reduced OS but this was not significant and (D) *IGHV*-unmutated groups showed significantly reduced OS.